Catalogue d'estampes des diverses écoles... / [expert] Vignères

[Vente. Estampes. 1858-04-10. Paris]

Catalogue de tableaux modernes, dessins... provenant du cabinet de monsieur le docteur F***... / [expert] Francis Petit

[Vente. Art. 1858-04-10. Paris]

Catalogue d'estampes anciennes et modernes... par suite du décès de M. J. [Jean] Bein... vente... 26 avril 1858 / [expert] Vignères

[Vente. Estampes. 1858-04-26. Paris]

Catalogue de tableaux et dessins modernes... / [expert] Francis Petit

[Vente. Art. 1859-02-26. Paris]

Catalogue des tableaux, vues d'Orient et autres par M. Louis Lottier... / [expert] Ch. Rouillard

[Vente. Art. 1859-03-03. Paris]

Notice d'estampes d'artistes... après décès de M. P.-F. Quénard,... / [expert] Vignères

[Vente. Estampes. 1859-04-26. Paris]

Catalogue de la première partie de la belle collection de tableaux anciens... composant la galerie de feu M. le comte de Houdetot,... / [expert] Ferdinand Laneuville

[Vente. Art. 1859-12-12 - 1859-12-14. Paris]

Catalogue des tableaux modernes composant la collection de M. le baron C***... [Courtier] / [expert] A. Couteaux

[Vente. Art. 1860-01-25. Paris]

Catalogue d'une belle collection de tableaux modernes... / [expert] A. Couteaux

[Vente. Art. 1860-03-07. Paris]

Catalogue de miniatures..., tableaux... provenant du cabinet de M. W... [Walferdin] / [expert] Vignères

[Vente. Art. 1860-05-18. Paris]

Catalogue d'estampes anciennes et modernes... / [expert] Vignères

[Vente. Estampes. 1860-05-21 - 1860-05-23. Paris]

Expertises croisées dans la dégénérescence maculaire liée à l'âge. Focus sur la physiopathologie, l'angiogenèse, les données pharmacologiques et cliniques [Review and expert opinion in age related macular degeneration. Focus on the pathophysiology, angiogenesis and pharmacological and clinical data].

Age related macular degeneration (AMD) is a pathological aging of the macula, brought about by the interaction of genetic and environmental factors. It induces geographic atrophy of the retina and/or choroidal neovascularization. In the latter, abnormal vessels develop from the choriocapillaris, with the involvement of VEGF (vascular endothelial growth factor). The VEGF family includes several factors, including VEGF-A, B, C, D, F and PlGF (placental growth factor). Their biological properties and their affinities to the VEGFR1, VEGFR2 and VEGFR3 receptors found on endothelial cells differ. Exudative AMD involves mainly VEGF-A and VEGF-R2. Anti-VEGF agents used in ophthalmology (ranibizumab, bevacizumab and aflibercept) are designed to primarily target this pathway. In vitro, all have sufficient affinity to their ligands. Their therapeutic efficacy must therefore be judged based on clinical criteria. In clinical practice, the minimum number of injections required for a satisfactory result appears to be comparable with all the three. The few available studies on therapeutic substitutions of anti-VEGF compounds suggest that some patients may benefit from substituting the anti-VEGF in cases of an unsatisfactory response to an initial molecule. Although local side effects, including increased risk of geographic atrophy, and systemic effects, including vascular accidents, have been suggested, these risks remain low, specially compared to the benefits of the treatment. Differences in safety between anti-VEGF are theoretically possible but unproven.

Cognitive Issues in Fingerprint Analysis: Inter- and Intra-Expert Consistency and the Effect of a "Target" Comparison

Deciding whether two fingerprint marks originate from the same source requires examination and comparison of their features. Many cognitive factors play a major role in such information processing. In this paper we examined the consistency (both between- and within-experts) in the analysis of latent marks, and whether the presence of a 'target' comparison print affects this analysis. Our findings showed that the context of a comparison print affected analysis of the latent mark, possibly influencing allocation of attention, visual search, and threshold for determining a 'signal'. We also found that even without the context of the comparison print there was still a lack of consistency in analysing latent marks. Not only was this reflected by inconsistency between different experts, but the same experts at different times were inconsistent with their own analysis. However, the characterization of these inconsistencies depends on the standard and definition of what constitutes inconsistent. Furthermore, these effects were not uniform; the lack of consistency varied across fingerprints and experts. We propose solutions to mediate variability in the analysis of friction ridge skin.

Catalogue d'estampes anciennes... provenant de la collection de M. R. D. [Robert-Dumesnil] / [expert] Defer

[Vente. Estampes. 1856-03-11. Paris]

Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus report.

Background: Symptom relief is the traditional treatment goal in Crohn's disease (CD). New goals including mucosal healing and bowel preservation are now achievable with tumor necrosis factor (TNF) antagonists. Infliximab and adalimumab are approved as second-line treatments for severe, active CD. Certolizumab pegol is approved only in the U.S. and Switzerland as second-line treatment for moderate-to-severe, active CD. Data from trials of infliximab suggest that high-risk patients and patients with active inflammation (CRP elevation and/or ileocolonic ulcers) may benefit from earlier use of this drug.